HK1063798A1 - Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers - Google Patents

Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers

Info

Publication number
HK1063798A1
HK1063798A1 HK04106661.1A HK04106661A HK1063798A1 HK 1063798 A1 HK1063798 A1 HK 1063798A1 HK 04106661 A HK04106661 A HK 04106661A HK 1063798 A1 HK1063798 A1 HK 1063798A1
Authority
HK
Hong Kong
Prior art keywords
rotamers
compositions
preparation
pharmaceutically active
increased amount
Prior art date
Application number
HK04106661.1A
Other languages
English (en)
Inventor
Suhan Tang
Wenxue Wu
Hongbiao Liao
David Tsai
Dinesh Gala
Andrew J Goodman
Gary Lee
Martin L Schwartz
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1063798A1 publication Critical patent/HK1063798A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK04106661.1A 2001-11-29 2004-09-03 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers HK1063798A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33433101P 2001-11-29 2001-11-29
US37391602P 2002-04-19 2002-04-19
PCT/US2002/038112 WO2003048153A1 (en) 2001-11-29 2002-11-26 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers

Publications (1)

Publication Number Publication Date
HK1063798A1 true HK1063798A1 (en) 2005-01-14

Family

ID=26989151

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04106661.1A HK1063798A1 (en) 2001-11-29 2004-09-03 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers

Country Status (12)

Country Link
US (2) US6943251B2 (xx)
EP (1) EP1451174B1 (xx)
JP (2) JP2005511693A (xx)
CN (1) CN1596254A (xx)
AR (1) AR037679A1 (xx)
AT (1) ATE478065T1 (xx)
AU (1) AU2002346569A1 (xx)
CA (1) CA2468525A1 (xx)
DE (1) DE60237388D1 (xx)
HK (1) HK1063798A1 (xx)
MX (1) MXPA04005210A (xx)
WO (1) WO2003048153A1 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689765B2 (en) * 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
AU2002346569A1 (en) * 2001-11-29 2003-06-17 Schering Corporation Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers
CN100396676C (zh) * 2002-03-29 2008-06-25 先灵公司 作为ccr5拮抗药的哌啶和哌嗪化合物的合成
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
JP2008526862A (ja) * 2005-01-06 2008-07-24 シェーリング コーポレイション ピペラジン化合物の薬学的な塩の調製
WO2007038496A2 (en) * 2005-09-27 2007-04-05 Chemic Laboratories, Inc. Synthesis of fatty alcohol esters of hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers
US7561458B2 (en) * 2006-12-26 2009-07-14 Texas Instruments Incorporated Ferroelectric memory array for implementing a zero cancellation scheme to reduce plateline voltage in ferroelectric memory
MX368805B (es) 2010-03-11 2019-10-17 Wyeth Llc Formulaciones orales y sales lipofílicas en metilnaltrexona.
WO2015200635A1 (en) * 2014-06-25 2015-12-30 Abbvie Inc. N-(4-{4-AMINO-7-[1-(2-HYDROXYETHYL)-1H-PYRAZOL-4-yl]THIENO[3,2-c]PYRIDIN-3-YL}PHENYL)-N'-(3-FLUOROPHENYL)UREA DOCUSATE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
BR0010304A (pt) * 1999-05-04 2002-02-13 Schering Corp Derivados de piperazina úteis como antagonistas do ccr5
JP3874229B2 (ja) * 1999-07-02 2007-01-31 Ｔｄｋ株式会社 圧電セラミックスおよびこれを用いた圧電デバイス
AU2002346569A1 (en) * 2001-11-29 2003-06-17 Schering Corporation Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers

Also Published As

Publication number Publication date
AU2002346569A8 (en) 2003-06-17
CA2468525A1 (en) 2003-06-12
WO2003048153A8 (en) 2004-06-03
AU2002346569A1 (en) 2003-06-17
JP2010132705A (ja) 2010-06-17
EP1451174A2 (en) 2004-09-01
US20050171117A1 (en) 2005-08-04
JP2005511693A (ja) 2005-04-28
MXPA04005210A (es) 2004-08-19
CN1596254A (zh) 2005-03-16
US6943251B2 (en) 2005-09-13
US7534884B2 (en) 2009-05-19
DE60237388D1 (de) 2010-09-30
ATE478065T1 (de) 2010-09-15
EP1451174B1 (en) 2010-08-18
WO2003048153A1 (en) 2003-06-12
AR037679A1 (es) 2004-12-01
US20030144510A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
TWI315204B (en) Oral dosage forms for propiverine or pharmaceutically acceptable salts thereof having prolonged release of the active agent
HUP0401763A3 (en) Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them and process for preparation the compounds
HUP0401642A3 (en) Use of staurosporine derivatives for the preparation of pharmaceutical compositions
HUP0004120A3 (en) Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy
HUP0401083A3 (en) 4-amino-6-phenyl-pyrrolo [2,3-d] pyrimidine derivatives, pharmaceutical compositions containing them and process for the preparation of the compounds
PL349894A1 (en) An improved process for the preparation of non-hygroscopic salts of l(-)-carnitine
AU2002341241A1 (en) Process for the preparation of fast dissolving dosage form
HUP0303487A3 (en) Compositions containing 3,7-diazabicyclo [3,3,1] compounds as anthiarhythmic agents and process for preparation of the compounds
HK1063798A1 (en) Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers
EP1407780A4 (en) PHARMACEUTICAL, STABLE HEMOSTATIC COMPOSITIONS
HUP0302594A3 (en) Process for the preparation of phenethylamine derivatives
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
GB0105893D0 (en) Pharmaceutically active compounds
GB0107751D0 (en) Pharmaceutically active compounds
HUP0303178A3 (en) Methods and compositions for reducing the taste of pharmaceutically active agents
GB0106631D0 (en) Pharmaceutically active compounds
HK1054926A1 (en) Process for the preparation of pyrazolopyrimidinones
EP1176150A4 (en) A METHOD FOR PRODUCING TRIFLUOROTHYMIDINE DERIVATIVES
HUP0200311A3 (en) Use of aroyl- or arylalkanoylpyridazines for preparation of pharmaceutical compositions
IL135993A0 (en) Pharmaceutical composition for the treatment of fibrosis
AU2002348105A1 (en) Oral dosage forms for improving the bioavailability of therapeutic agents
SI1283845T1 (en) Process for the preparation of pharmaceutically acceptable salts of (ss-rs)-s-adenosyl-l-methionine
IL136687A0 (en) Pharmaceutical composition for the treatment of multiple sclerosis
HU0003973D0 (en) Pharmaceutical composition for the treatment of aids
AU2002313877A1 (en) The process for the preparation of the acesulfam salts

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131126